Can Dupixent Be Administered During 12-Month-Old Vaccines?
Yes, Dupixent (dupilumab) can be administered to a 12-month-old child receiving routine vaccinations, but live vaccines (MMR, varicella) should ideally be avoided during active Dupixent treatment according to FDA labeling, though emerging evidence suggests they may be safe when given concurrently.
FDA Labeling Guidance
The official FDA label for Dupixent explicitly states: "Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT." 1 The label acknowledges that it is unknown if administration of live vaccines during Dupixent treatment will impact the safety or effectiveness of these vaccines, and limited data are available regarding coadministration with non-live vaccines.
Routine 12-Month Vaccines
At 12 months of age, children typically receive:
- Live vaccines: MMR (measles, mumps, rubella) and varicella 2
- Non-live vaccines: Hepatitis A, Hib booster, pneumococcal conjugate, and potentially DTaP 2, 3
Practical Approach
For Non-Live Vaccines (Hepatitis A, Hib, PCV, DTaP)
These can be safely administered concurrently with Dupixent without timing restrictions. There is no theoretical concern for interference or safety issues with inactivated vaccines during biologic therapy 3.
For Live Vaccines (MMR and Varicella)
Option 1 (FDA-Compliant, Most Conservative):
- Complete MMR and varicella vaccines before starting Dupixent
- Wait at least 2 weeks after live vaccination before initiating Dupixent
- This ensures vaccine response is not potentially impaired
Option 2 (Evidence-Based Alternative with Shared Decision-Making): Recent clinical evidence challenges the blanket avoidance recommendation:
A 2024 systematic review and expert Delphi consensus from the American College of Allergy, Asthma and Immunology concluded that vaccines (including live vaccines) can be administered to patients receiving dupilumab in a shared decision-making capacity 4
Multiple case series have documented safe administration of MMR and varicella vaccines in dupilumab-treated children with no adverse events reported within 4 weeks post-vaccination 5, 6, 7
One study reported 9 children with severe atopic dermatitis who received MMR ± varicella while on dupilumab (some with as little as 1-7 weeks gap from last dose) with no treatment-emergent adverse events or infections within 4 weeks 7
Mechanistic Rationale
Dupilumab blocks IL-4 and IL-13 signaling, which primarily affects type 2 immunity (allergic/eosinophilic responses). It does not broadly suppress cellular immunity or interfere with T-cell responses to viral antigens in the same way as traditional immunosuppressants (corticosteroids, methotrexate, TNF inhibitors). This mechanistic difference explains why live vaccines may be safer with dupilumab than with other immunosuppressive therapies 4, 8.
Clinical Decision Algorithm
If the child has not yet started Dupixent:
- Administer all 12-month vaccines (including MMR and varicella) first
- Wait 2 weeks
- Initiate Dupixent
If the child is already on Dupixent and needs 12-month vaccines:
- Administer all non-live vaccines (Hepatitis A, Hib, PCV, DTaP) without delay
- For MMR and varicella:
- Conservative approach: Hold Dupixent for 4 weeks before vaccination, administer vaccines, then wait 2 weeks before resuming Dupixent
- Evidence-based alternative: Administer MMR and varicella while continuing Dupixent after thorough shared decision-making discussion with parents about:
- Theoretical (but not clinically demonstrated) risk of vaccine-associated infection
- Risk of atopic dermatitis flare if Dupixent is held
- Emerging safety data supporting concurrent administration
- Importance of timely vaccination for disease prevention
Important Caveats
- Rotavirus vaccine is not relevant at 12 months (must be completed by 8 months of age) 2
- The 2021 consensus recommendations suggest completing routine childhood vaccinations before starting dupilumab when feasible, but acknowledge this may not always be practical 8
- Monitor for 4 weeks post-vaccination for any signs of vaccine-associated infection (fever, rash progression, systemic symptoms)
- Document the shared decision-making process in the medical record
- Consider consulting pediatric dermatology or allergy/immunology for complex cases
Bottom Line
Non-live vaccines can be given without restriction. For live vaccines at 12 months, the safest approach is to complete them before starting Dupixent, but emerging evidence supports concurrent administration when necessary through shared decision-making, particularly given dupilumab's targeted mechanism that does not broadly suppress antiviral immunity.